Journal of microencapsulation · 2026
Hyaluronic acid-modified PLGA nanoparticles for enhanced ocular drug delivery.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Sa, Tang Tianyu, He Huashen, Li Fan, Su Bisen, Li Shuguang, Ban Junfeng, Jia Huanhuan, Chen Hui
Аннотация
AIM: To develop hyaluronic acid (HA)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (HA-PLGA NPs) for enhanced triamcinolone acetonide (TA) ocular delivery.
METHODS: HA-PLGA NPs were prepared via solvent evaporation. Physicochemical properties, in vitro corneal permeation, and in vivo pharmacokinetics in rabbit aqueous humour were evaluated.
RESULTS: HA modification significantly increased encapsulation efficiency from 22.26 ± 0.8% to 62.87 ± 3.9% (w/w) and drug loading from 2.21 ± 0.08% to 6.09 ± 0.38% (w/w). Apparent permeability coefficient increased from 2.33 ± 0.14 to 9.28 ± 0.58 (×10-6cm·s-1). In vivo, HA-PLGA NPs achieved a 7.2-fold higher area under the curve (AUC0→360) (8.06 μg·mL-1·min) compared to unmodified nanoparticles.
CONCLUSIONS: HA-PLGA NPs provide a high-efficiency, non-invasive platform for treating posterior segment diseases by overcoming ocular barriers through bioadhesion.
METHODS: HA-PLGA NPs were prepared via solvent evaporation. Physicochemical properties, in vitro corneal permeation, and in vivo pharmacokinetics in rabbit aqueous humour were evaluated.
RESULTS: HA modification significantly increased encapsulation efficiency from 22.26 ± 0.8% to 62.87 ± 3.9% (w/w) and drug loading from 2.21 ± 0.08% to 6.09 ± 0.38% (w/w). Apparent permeability coefficient increased from 2.33 ± 0.14 to 9.28 ± 0.58 (×10-6cm·s-1). In vivo, HA-PLGA NPs achieved a 7.2-fold higher area under the curve (AUC0→360) (8.06 μg·mL-1·min) compared to unmodified nanoparticles.
CONCLUSIONS: HA-PLGA NPs provide a high-efficiency, non-invasive platform for treating posterior segment diseases by overcoming ocular barriers through bioadhesion.